Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026. A fireside chat featuring Bernard Coulie, M.D., Ph.D., CEO, and Keith Cummings, M.D., CFO, is scheduled for Feb 25, 2026 at 2:40 p.m. ET.

According to the company, the live webcast will be accessible via Pliant’s Investor Relations events page, and a replay will be archived on the Pliant website for 30 days after the event.

News Market Reaction – PLRX

-0.81%

1 alert

-0.81% News Effect

On the day this news was published, PLRX declined 0.81%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 36th Annual Conference dates: February 25–26, 2026 Fireside chat time: 2:40 p.m. ET +1 more

4 metrics

Conference edition 36th Annual Oppenheimer Healthcare Life Sciences Conference

Conference dates February 25–26, 2026 Oppenheimer conference schedule

Fireside chat time 2:40 p.m. ET Scheduled PLRX fireside chat on February 25, 2026

Webcast replay window 30 days Replay archived on company website after the event

Market Reality Check

Price: $1.30 Vol: Volume 528,787 is below t...

low vol

$1.30 Last Close

Volume Volume 528,787 is below the 20-day average of 954,082 (relative volume 0.55). low

Technical Shares at $1.24 are trading below the 200-day MA of $1.44 and far under the 52-week high of $3.46.

Peers on Argus

PLRX fell 4.62% with several biotech peers also down intraday (e.g., ATOS -4.22%...

PLRX fell 4.62% with several biotech peers also down intraday (e.g., ATOS -4.22%, SRZN -1.70%, SAVA -1.39%), but no peers appeared in the momentum scanner and sector selling was not flagged as a coordinated move.

Historical Context

3 past events · Latest: Dec 04 (Positive)

Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Clinical data update	Positive	-15.6%	Interim Phase 1 PLN-101095 data showed responses in ICI-refractory tumors.
Dec 01	Conference participation	Neutral	-5.0%	Announcement of participation and fireside chat at Piper Sandler conference.
Nov 06	Earnings and update	Positive	-6.7%	Q3 2025 financials, PLN-101095 enrollment completion, and cash position disclosure.

Pattern Detected

Recent news, including positive clinical data and a corporate update, was followed by negative 24-hour price reactions, suggesting a pattern of selloffs on positive or neutral headlines.

Recent Company History

Over the last few months, PLRX has released several material updates. On Nov 6, 2025, a Q3 2025 update highlighted lower R&D and G&A expenses and strong cash of $243.3M, yet shares fell 6.71%. On Dec 4, 2025, encouraging Phase 1 data for PLN-101095, including a 15-month median time on treatment for responders, led to a 15.58% decline. A conference participation notice on Dec 1, 2025 also saw a 4.97% drop, echoing today’s conference-focused announcement.

Market Pulse Summary

This announcement highlights Pliant’s participation in an investor-focused healthcare conference, wi...

Analysis

This announcement highlights Pliant’s participation in an investor-focused healthcare conference, with management scheduled for a fireside chat on February 25, 2026. In recent months, the company reported encouraging clinical data and a detailed Q3 2025 update, yet those events were followed by short-term share price weakness. Investors may watch for any new clinical, financial, or strategic disclosures emerging from the conference that build on prior updates and clarify the company’s development trajectory.

Key Terms

integrin-based therapeutics

1 terms

integrin-based therapeutics medical

"focused on the discovery and development of integrin-based therapeutics"

Integrin-based therapeutics are drugs or biologic treatments that target integrins, which are proteins on cell surfaces that act like Velcro and signaling switches to help cells stick to each other and respond to their environment. By blocking or activating these proteins, such therapies can change inflammation, tissue repair, cancer spread or clotting, so investors watch them as potential high-impact treatments that can create new markets, move clinical-stage valuations, and carry clinical and regulatory risk.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026. 

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. Eastern Time.

Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of α_vß₈ and α_vß₁ integrins, that is being developed for the treatment of solid tumors. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When will Pliant Therapeutics (PLRX) present at the Oppenheimer conference in 2026?

Pliant Therapeutics will present on February 25, 2026 at 2:40 p.m. ET. According to the company, the presentation is a fireside chat with CEO Bernard Coulie and CFO Keith Cummings during the virtual Oppenheimer Healthcare Life Sciences Conference.

How can investors watch the PLRX fireside chat on February 25, 2026?

Investors can watch the PLRX fireside chat via a live webcast on Pliant’s Investor Relations events page. According to the company, the webcast link is available on the company website and the replay will be archived for 30 days.

Who will speak for Pliant Therapeutics (PLRX) at the February 2026 conference?

Pliant will be represented by Bernard Coulie, M.D., Ph.D. (CEO) and Keith Cummings, M.D. (CFO) in a fireside chat. According to the company, both executives will participate in the virtual session on February 25, 2026.

Will the PLRX webcast from the Oppenheimer conference be available after the live event?

Yes, the PLRX webcast replay will be archived on the Pliant website for 30 days following the event. According to the company, interested parties can access the replay via the Investor Relations events and presentations page.

What topics will PLRX cover in the February 25, 2026 fireside chat at Oppenheimer?

The company scheduled a fireside chat featuring PLRX leadership; topic specifics were not detailed in the notice. According to the company, the session will feature CEO and CFO remarks and is accessible via the company webcast on February 25, 2026.